SCHEMBL19923086

SCHEMBL19923086

Brc1ccc(NCC2CCOC2)nc1C1OCCO1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRPC5 Q9UL62 1/20 0.36
▸ CCNT1 O60563 10/20 0.35
▸ KCNH3 Q9ULD8 1/20 0.34
▸ PDCD1 Q15116 1/20 0.34
▸ CD274 Q9NZQ7 1/20 0.34
▸ CDK9 P50750 2/20 0.33
▸ IRAK1 P51617 1/20 0.33
▸ PIK3CA P42336 2/20 0.33
▸ PIK3C2B O00750 1/20 0.33
▸ CLK1 P49759 1/20 0.33
▸ CLK2 P49760 1/20 0.33
▸ CLK3 P49761 1/20 0.33
▸ DYRK1A Q13627 1/20 0.33
▸ PIP4K2C Q8TBX8 1/20 0.33
▸ CLK4 Q9HAZ1 1/20 0.33
▸ PI4KB Q9UBF8 1/20 0.33
▸ DYRK1B Q9Y463 1/20 0.33
▸ GRM4 Q14833 1/20 0.32
▸ NAMPT P43490 1/20 0.32
▸ PIM1 P11309 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18095718 0.83 CCNT1 (0.36) TRPC5CCNT1KCNH3CDK9IRAK1
SCHEMBL18095740 0.82 TRPC5 (0.36) TRPC5CCNT1KCNH3CDK9IRAK1
SCHEMBL28577470 0.78 HCAR3 (0.32) —
SCHEMBL18095774 0.77 KCNH2 (0.32) —
SCHEMBL19923108 0.77 CCNT1 (0.43) TRPC5CCNT1KCNH3PDCD1CD274
SCHEMBL18095702 0.76 TRPC5 (0.33) TRPC5CCNT1IRAK1PIK3C2BCLK1
SCHEMBL22023306 0.72 BTK (0.40) TRPC5CCNT1CDK9IRAK1NAMPT
SCHEMBL18095762 0.72 MEN1 (0.35) —
SCHEMBL12501838 0.68 CCNT1 (0.49) CCNT1CDK9IRAK1CLK1CLK2
SCHEMBL22026611 0.68 CCNT1 (0.37) TRPC5CCNT1KCNH3PDCD1CD274

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10786492-B2 Formylated N-heterocyclic derivatives as FGFR4 inhibitors NOVARTIS AG (CH) 2020-09-29 — — US disclosed
EP-3274344-B1 FORMYLATED N-HETEROCYCLIC DERIVATIVES AS FGFR4 INHIBITORS NOVARTIS AG (CH) 2019-04-24 — — EP disclosed
US-20190105309-A1 Formylated N-heterocyclic derivatives as FGFR4 inhibitors. NOVARTIS PHARMA AG (CH) 2019-04-11 — — US disclosed
US-10189813-B2 Formylated N-heterocyclic derivatives as FGFR4 inhibitors NOVARTIS AG (CH) 2019-01-29 — — US disclosed
US-20180065951-A1 Formylated N-heterocyclic derivatives as FGFR4 inhibitors NOVARTIS PHARMA AG (CH) 2018-03-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190105309-A1 Formylated N-heterocyclic derivatives as FGFR4 inhibitors. FGFR4, FGFR1, FGFR3 TRPC5 1395/4885CCNT1 1818/4885KCNH3 2701/4885
US-20180065951-A1 Formylated N-heterocyclic derivatives as FGFR4 inhibitors FGFR4, FGFR1, FGFR3 TRPC5 1231/4885CCNT1 1725/4885KCNH3 2641/4885
US-10189813-B2 Formylated N-heterocyclic derivatives as FGFR4 inhibitors FGFR4, FGFR1, FGFR3 TRPC5 1231/4885CCNT1 1725/4885KCNH3 2641/4885
US-10786492-B2 Formylated N-heterocyclic derivatives as FGFR4 inhibitors FGFR4, FGFR1, FGFR3 TRPC5 1231/4885CCNT1 1725/4885KCNH3 2641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback